DrugPatentWatch Database Preview
Drugs in Development Information for AZD-8055
Drug Development Status for AZD-8055: Patents, clinical trial progress, indications
AZD-8055 is an investigational drug.
There have been 30 clinical trials for AZD-8055.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.
The most common disease conditions in clinical trials are Lung Neoplasms, Adenocarcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
There are fifty-one US patents protecting this investigational drug and five hundred and seventy-five international patents.
Summary for AZD-8055
| US Patents | 51 |
| International Patents | 575 |
| US Patent Applications | 139 |
| WIPO Patent Applications | 70 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2010-12-01) |
| Vendors | 67 |
Recent Clinical Trials for AZD-8055
| Title | Sponsor | Phase |
|---|---|---|
| Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | National Cancer Institute (NCI) | Phase 2 |
| Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | M.D. Anderson Cancer Center | Phase 2 |
| Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer | AstraZeneca | Phase 2 |
Clinical Trial Summary for AZD-8055
Top disease conditions for AZD-8055
Top clinical trial sponsors for AZD-8055
US Patents for AZD-8055
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD-8055 | Start Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | Start Trial |
| AZD-8055 | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| AZD-8055 | Start Trial | Antibody drug conjugates | Novartis AG (Basel, CH) | Start Trial |
| AZD-8055 | Start Trial | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KuDOS Pharmaceuticals Limited (London, GB) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD-8055
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD-8055 | European Patent Office | 3131552 | 2034-04-16 | Start Trial |
| AZD-8055 | Japan | 2017514806 | 2034-04-16 | Start Trial |
| AZD-8055 | Japan | 2019070012 | 2034-04-16 | Start Trial |
| AZD-8055 | New Zealand | 629860 | 2034-04-16 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
